This health-economic analysis investigated the cost, cost-effectiveness and cost-utility of intravenous paricalcitol compared with oral calcitriol and oral and intravenous alfacalcidol.

Tamura et al. 28 compared intravenous maxacalcitol (thrice weekly) to oral calcitriol (twice weekly) over 24 weeks (23 patients per group). Doses were adjusted to minimize hypercalcemia.